Recently, several PARPi have been approved by the FDA (Food and Drug Administration) to treat different cancers, which include metastatic TNBC and estrogen receptor negative (ER-)/HER2+ breast cancer with BRCA (BReast CAncer type 1 and type 2 genes) -mutations. The gene discussed is ERBB2; the disease is breast carcinoma.